Galera Therapeutics (GRTX) Competitors $0.03 +0.00 (+2.90%) As of 03:02 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock GRTX vs. HOTH, BFRI, OMGA, ALZN, ALBT, GTBP, SNGX, AEZS, CANF, and FRTXShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Hoth Therapeutics (HOTH), Biofrontera (BFRI), Omega Therapeutics (OMGA), Alzamend Neuro (ALZN), Avalon GloboCare (ALBT), GT Biopharma (GTBP), Soligenix (SNGX), Aeterna Zentaris (AEZS), Can-Fite BioPharma (CANF), and Fresh Tracks Therapeutics (FRTX). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Hoth Therapeutics Biofrontera Omega Therapeutics Alzamend Neuro Avalon GloboCare GT Biopharma Soligenix Aeterna Zentaris Can-Fite BioPharma Fresh Tracks Therapeutics Galera Therapeutics (NASDAQ:GRTX) and Hoth Therapeutics (NASDAQ:HOTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends. Does the MarketBeat Community prefer GRTX or HOTH? Hoth Therapeutics received 27 more outperform votes than Galera Therapeutics when rated by MarketBeat users. Likewise, 66.96% of users gave Hoth Therapeutics an outperform vote while only 54.35% of users gave Galera Therapeutics an outperform vote. CompanyUnderperformOutperformGalera TherapeuticsOutperform Votes5054.35% Underperform Votes4245.65% Hoth TherapeuticsOutperform Votes7766.96% Underperform Votes3833.04% Do analysts prefer GRTX or HOTH? Hoth Therapeutics has a consensus price target of $4.00, indicating a potential upside of 328.77%. Given Hoth Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Hoth Therapeutics is more favorable than Galera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Hoth Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has more risk and volatility, GRTX or HOTH? Galera Therapeutics has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, Hoth Therapeutics has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500. Which has better earnings and valuation, GRTX or HOTH? Hoth Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.35-0.08Hoth TherapeuticsN/AN/A-$7.84M-$1.33-0.70 Is GRTX or HOTH more profitable? Galera Therapeutics' return on equity of 0.00% beat Hoth Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Hoth Therapeutics N/A -89.68%-82.61% Does the media prefer GRTX or HOTH? In the previous week, Hoth Therapeutics had 10 more articles in the media than Galera Therapeutics. MarketBeat recorded 10 mentions for Hoth Therapeutics and 0 mentions for Galera Therapeutics. Hoth Therapeutics' average media sentiment score of 0.30 beat Galera Therapeutics' score of 0.00 indicating that Hoth Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Galera Therapeutics Neutral Hoth Therapeutics Neutral Do insiders and institutionals hold more shares of GRTX or HOTH? 50.8% of Galera Therapeutics shares are owned by institutional investors. Comparatively, 7.1% of Hoth Therapeutics shares are owned by institutional investors. 12.9% of Galera Therapeutics shares are owned by company insiders. Comparatively, 10.6% of Hoth Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. SummaryHoth Therapeutics beats Galera Therapeutics on 10 of the 16 factors compared between the two stocks. Remove Ads Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.55M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-0.086.9923.2518.07Price / SalesN/A198.60361.2686.80Price / CashN/A65.6738.1634.64Price / Book-0.015.926.493.99Net Income-$59.08M$142.37M$3.21B$247.18M7 Day PerformanceN/A-9.32%-6.42%-6.42%1 Month PerformanceN/A-10.26%-0.68%-7.44%1 Year PerformanceN/A-15.08%6.05%-4.31% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.03+2.9%N/A-81.7%$1.55MN/A-0.0830HOTHHoth Therapeutics2.8753 of 5 stars$1.07-0.9%$4.00+273.8%-28.6%$7.39MN/A-0.814Earnings ReportAnalyst ForecastNews CoverageBFRIBiofrontera1.9588 of 5 stars$0.90+4.8%$7.00+676.7%-54.0%$6.98M$35.36M-0.4070Short Interest ↑OMGAOmega Therapeutics1.905 of 5 stars$0.13-21.8%$9.20+7,260.0%-95.8%$6.92M$8.10M-0.09120Gap UpALZNAlzamend Neuro3.392 of 5 stars$1.02+1.0%$20.00+1,860.8%-88.6%$6.73MN/A0.004ALBTAvalon GloboCare1.6313 of 5 stars$5.97-5.1%N/A-2.7%$6.53M$1.31M-0.305Positive NewsGTBPGT Biopharma3.1152 of 5 stars$2.33-6.8%$11.00+372.1%-46.1%$5.91MN/A-0.338SNGXSoligenix1.4524 of 5 stars$2.29-4.2%N/A-74.4%$5.75M$840,000.00-0.3020AEZSAeterna ZentarisN/A$3.20-6.7%N/A-66.0%$5.74M$2.37M-0.2220Analyst ForecastGap DownHigh Trading VolumeCANFCan-Fite BioPharma1.7911 of 5 stars$1.62+1.3%$14.00+764.2%-29.3%$5.74M$667,000.00-0.918Analyst ForecastHigh Trading VolumeFRTXFresh Tracks TherapeuticsN/A$0.94-0.5%N/A+5.0%$5.59M$10.06M-0.6620 Remove Ads Related Companies and Tools Related Companies HOTH Competitors BFRI Competitors OMGA Competitors ALZN Competitors ALBT Competitors GTBP Competitors SNGX Competitors AEZS Competitors CANF Competitors FRTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GRTX Stock Free GRTX Stock Alerts